Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.


Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Biosimilars Canada Announces Board Chair and Vice-Chair

Biosimilars Canada is pleased to announce the unanimous election of Mr. Mike Woolcock, Senior Vice President of the Apobiologix division of Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President and Managing Director of Organon Canada, has been unanimously elected as Vice-Chair of the Biosimilars Canada Board.
Read more

Ontario biosimilars policy could cut drug costs for plan sponsors: expert

Read more

Ontario government expands use of biosimilar drugs

Read more